Canopy Growth (NASDAQ: CGC) has lost 99% of its value since Canada’s legalization of recreational cannabis in 2018, with shares currently trading below $2. The company’s net revenue for Q4 of fiscal year 2025 was CA$65 million, marking an 11% decline year-over-year, despite a 4% increase in Canadian cannabis revenue. Additionally, Canopy Growth reported a net loss per share of CA$1.43, up from CA$1.03 the previous year.
The company, which operates internationally through subsidiaries like Storz & Bickel, aims to improve financial health by reducing total debt by 49% and targeting positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). However, analysts question the viability of these goals, especially in a highly regulated and competitive cannabis market.
Overall, despite its presence in the U.S. market and ongoing efforts to cut costs, Canopy Growth is viewed as unattractive for investors, with little immediate hope for recovery in profitability or revenue growth.
